A method of increasing megakaryocyte production is disclosed.

Also disclosed are novel megakaryocyte differentiation factors and platelets obtained from the differentiated megakaryocytes.

This factor capable of promoting the colony-forming of megacaryocytes, enlarging the size of megakaryocytes, stimulating the proliferation of multipotential stem cell.

The present invention relates to cytokines supporting progenitor cell proliferation, cytokines supporting differentiation of pluripotent progenitor cells to megakaryocytes, or cytokines supporting platelet formation by megakaryocytes.

Novel human megakaryocyte stimulating factors (MSFs) capable of stimulating the growth and development of colonies of megakaryocytes, pharmaceutical compositions containing same, and methods for their preparation and use are provided.

A novel human megakaryocytopoietic growth promoting activity factor capable of stimulating the growth of megakaryocytes and augments the differentiation or maturation of megakaryocytes.

Methods for generating megakaryocyte and platelets are also provided.

Megakaryocytes mature under the influence of erythropoietin.

The present invention provides a method of generating megakaryocytes and platelets.

Differentiated megakaryocytes produced by introducing an activated oncogene into blast-megakaryocytes is disclosed.

Primary thrombocytosis (due to proliferation of megakaryocytes)

The proper in vitro culture of megakaryocytes results in the production and shed of platelets.

Primary thrombocytosis (due to proliferation of megakaryocytes)

Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells.

The mice exhibit decreased platelet counts and/or megakaryocyte leukemia.